Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech Will Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
Apr 28, 2003
|
50.7 KB
|
| |
Palo Alto, Calif., April 28, 2003 -- Corgentech Inc., a privately-held biotechnology company, today announced John P. McLaughlin, the company's president and chief executive officer, will present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference entitled "Breakthrough Therapeutics: Leading Experts and...
|
|
|
Corgentech Appoints Patricia Oto Vice President for Regulatory Affairs and Quality Assurance
Apr 22, 2003
|
48.8 KB
|
| |
Palo Alto, Calif., April 22, 2003 -- Corgentech Inc., a privately-held biotechnology company, announced today that Patricia A. Oto, R.Ph., has been promoted to vice president for regulatory affairs and quality assurance. Ms. Oto was formerly senior director of regulatory affairs and quality assurance for the company.
In her new r...
|
|
|
Corgentech Selected to Present at Future Leaders in Biotech Industry Conference
Apr 1, 2003
|
48.5 KB
|
| |
Palo Alto, Calif., April 1, 2003 -- Corgentech Inc., a privately-held biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Future Leaders in the Biotech Industry Conference. His presentation will be held on Thursday, April 3 from 1:20 to 1:45 p.m. EST, in ...
|
|
|
Corgentech Appoints Jack Regan Vice President for Manufacturing
Mar 5, 2003
|
48.4 KB
|
| |
Palo Alto, Calif., March 5, 2003 -- Corgentech Inc., a privately-held biotechnology company, announced today that Jack Regan has been appointed vice president for manufacturing. Mr. Regan joins Corgentech from Genentech, where he served as senior director of manufacturing collaborations.
At Corgentech, he will be responsible fo...
|
|
|
Corgentech Receives FDA Fast Track Status for Drug to Prevent "AV Graft" Failure in End-Stage Renal Disease Patients
Jan 23, 2003
|
62.8 KB
|
| |
-- Company Plans to Start Phase I/II Trial Shortly --
Palo Alto, Calif., January 23, 2003 -- Corgentech Inc., a privately-held biotechnology company, announced today that the United States Food and Drug Administration (FDA) has granted fast track designation for the company's second product, CGT021, whic...
|
|
|
Click here to download our most recent fact sheet.